Other languages Daxor Corporation Nyse

Equities

DXR

US2394671034

Market Closed - Nyse Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
9.8 ^USD	-0.81%		+1.55%	+2.08%

16/04	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
10/04	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	16/04
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	10/04
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite	25/03
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	16/03
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	11/03
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis	08/03
Daxor Corporation Announces Two Significant New Customer Transactions with Daxor's BVA-100 in January 2024	12/02
Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer	02/01
Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers	13/11
Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting	11/23/11
Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29
JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®	10/23/10
Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy	12/23/12
Daxor Says its Blood Volume Analysis Test Picked Up by Five US Hospitals	11/23/11
Daxor Corporation Announces Further Acquisitions and Increased Utilization of Its Bva 100(R) Blood Volume Diagnostic Throughout the U.S	11/23/11
Daxor Gets $1.1 Million Contract From US Defense Health Agency	06/23/06
Top Premarket Decliners	22/23/22
Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients	23/23/23
Daxor Prices $2 Million Common Stock Offering	15/22/15
Wall Street Set to Open Sharply Higher on Lower-Than-Expected Wholesale Inflation	15/22/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daxor Corporation Nyse

Equities

DXR

US2394671034

Other languages

Filters